The method cannot be used to measure the amount of each 13II-labelled compound quantitatively because of the losses of organic radioiodine (see Table 1 ) at each step. Quantitative analyses of the organic radioiodine fraction is probably best performed by removal of iodide on a column of silver chloride followed by butanol extraction and paper chromatography of the remaining organic iodine compounds. The method described here is primarily useful for concentrating the organic iodine compounds for qualitative study. Its use is limited to urines of relatively high radioactivity, at least 0 003 Kc of organic radioiodine/ml., and it is therefore not applicable to study of organic radioiodine compounds of urine after tracer doses of 131I. As the method is not quantitative, the relative amount of each component does not give any insight into the turnover of iodine in vivo, and may in fact reflect merely the efficiency of the method, some compounds being more completely recovered than others. SUMMARY 1. A method for fractionation of urinary radioiodine activity after l3lJ therapy has been modified to give improved resolution and recovery of organic radioiodine compounds.
The method cannot be used to measure the amount of each 13II-labelled compound quantitatively because of the losses of organic radioiodine (see Table 1 ) at each step. Quantitative analyses of the organic radioiodine fraction is probably best performed by removal of iodide on a column of silver chloride followed by butanol extraction and paper chromatography of the remaining organic iodine compounds. The method described here is primarily useful for concentrating the organic iodine compounds for qualitative study. Its use is limited to urines of relatively high radioactivity, at least 0 003 Kc of organic radioiodine/ml., and it is therefore not applicable to study of organic radioiodine compounds of urine after tracer doses of 131I. As the method is not quantitative, the relative amount of each component does not give any insight into the turnover of iodine in vivo, and may in fact reflect merely the efficiency of the method, some compounds being more completely recovered than others. SUMMARY 1. A method for fractionation of urinary radioiodine activity after l3lJ therapy has been modified to give improved resolution and recovery of organic radioiodine compounds.
2. The organic radioiodine compounds of the urine after 131I therapy for thyroid carcinoma were divided into four fractions, one ofwhich (fraction A) contained di-iodotyrosine and 3:5-di-iodo-4-hydroxyphenyl-lactic acid, previously identified by Fletcher (1957b) . 3. After l3ll therapyforthyrotoxicosis, fractionA was isolated from the urine but the other fractions were not detected.
4. The method is not suitable for analysis of urines excreted after tracer doses of 131J, nor for quantitative measurement of the amounts of the organic radioiodine compounds of urine after 1311 therapy.
Radioiodine Compounds of Human Urine after 131I Therapy Thyroxine is the major iodine-containing compound in the circulation (Taurog & Chaikoff, 1948) but in certain circumstances, for example after administration of 131I in therapeutic amounts for the treatment of thyroid carcinoma or thyrotoxicosis, labelled thyroxine (Robbins & Rall, 1952; Gordon, Gross, O'Connor & Pitt-Rivers, 1952) , 3:5:3'-tri-iodothyronine (Gross & PittRivers, 1952) , 3:5-di-iodotyrosine and 3-monoiodotyrosine (Benua & Dobyns, 1955) , thyroglobulin (Robbins & Rall, 1952) and an iodoprotein resembling serum albumin (Robbins, Rall & Rawson, 1955) may also be found. The labelled iodine compounds of urine have not been as thoroughly investigated as those of plasma. 3:5-Di-iodotyrosine and thyroxine were reported to be present by Rall (1950) , thyroxine and 3:5:3'-triiodothyronine by Horst & Heuwieser (1957) . Fletcher (1957a, b) detected a total of eight labelled iodine compounds in the urine 6-7 days after 131J therapy for thyroid carcinoma. Two were identified as 3:5-di-iodotyrosine and 3:5-di-iodo-4-hydroxyphenyl-lactic acid, but neither thyroxine nor 3:5:3'-tri-iodothyronine was detected. With the method developed by Fletcher (1957 a), modified as described in the preceding paper, some of the unidentified urinary iodine compounds were isolated for further study. v/v) .
METHODS AND MATERIALS
The following compounds were compared by chromatography with the 131I compounds of urine.
Thyroxine, 3:5:3'-tri-iodothyronine, 3:5-di-iodothyronine (which were obtained from Glaxo Ltd.), 3-monoiodothyronine, tetraiodothyroacetic acid and 3:5:3'-tri-iodothyroacetic acid, 3:5-di-iodotyrosine, 3-monoiodotyrosine [which was prepared by the iodination of tyrosine (Fletcher, 1956) ], 3:5-di-iodo-4-hydroxyphenyl-lactic acid, 3:5-di-iodo-4-hydroxyphenylpyruvic acid [prepared by iodination of 4-hydroxyphenylpyruvic acid, which was prepared by the method of Saul & Trikojus (1948) ], 3:3'-di-iodothyronine and 3:3':5'-tri-iodothyronine [which were prepared in solution by the procedure of Gemmill (1956) for the stepwise iodination of 3-monoiodothyronine]. The R, values of these compounds are given in Table 1 .
Radioautographs of the chromatograms were made with flford Industrial X-ray film. The carrier iodine compounds were located by staining the chromatograms with a solution of equal parts of ceric sulphate (low in rare earths, 1 %, w/v in N-H2S04) and sodium arsenite [5% (w/v) in N-H2SO4] mixed immediately beforehand (Bowden, Maclagan & Wilkinson, 1955) , the strips then being sprayed with a 1 % (w/v) solution of o-phenylenediamine in acetone . In the latter part of this work the chromatograms were then sprayed with concentrated NH3 solution which neutralized the N-H2504, thus prolonging the life of the paper.
Ox-spleen fi-glucuronidase was obtained from L. Light and Co. Ltd.
RESULTS
Chromatographic comparison of urinary M31I-labelled compounds with compounds of known structure The urinary radioiodine compounds were isolated by the method described in the preceding paper from the urine of thyrotoxic and thyroid-carcinoma patients who had received therapeutic doses of 131I. In the final step of the procedure, the '3I-Ilabelled compounds were eluted from a paper chromatogram in ethanol-aq. v/v) . A portion of the solution, estimated to contain 0-004-0-01 luc of 131I, was concentrated under reduoed pressure at 500 to a few drops, which were applied as a single spot on a line 4 in. from the end of a sheet of chromatography paper, 18 in. in length. Of a solution of compounds of known structure in ethanol-aq. 2N-NH3 soln. (1:1, v/v), a volume estimated to contain 50 pg. of each was applied to the same spot. After development in one of the solvent systems described, the chromatogram was stapled to X-ray film and stored for 2 weeks. The chromatogram was developed by the staining procedure described and the position of the compounds of known structure thus detected was compared with that of the blackened spots on the radioautograph. Table 2 presents a summary of experiments in which radioiodine 'compounds isolated from urine had the same chromatographic properties as one of the iodine compounds of known structure used as a carrier.
Degradation of urinary M31I-labelled compounds Two separate 131I-labelled compounds formed the component of organic iodine which ran between iodide and thyroxine in butanol-dioxan-aq. NH3 Table 1 . R values of iodine compounds u8ed in chromatography The slower-running compound, with R. 0-48 in this solvent, did not have the same chromatographic properties as any of the iodine compounds of known structure which were run at the same time.
As this compound always contained a relatively important proportion of the label in fraction B, it was selected for further study.
A sample of this slower-running compound was taken up in 10 ml. of 2N-NaOH and heated in a water bath at 40-50o. Samples were taken for chromatographic analysis at 0, 1-5 and 3 hr. Each was neutralized and evaporated to a volume of only a few drops under reduced pressure. The residual solution was removed by pipette from the salt which had crystallized. The salt was washed with a few drops of ethanol, which were added to the residual solution. The process was repeated two or three times until the solution to be analysed was sufficiently free of salts to be applied across the width of a strip of chromatography paper (1.5 in. x 18 in.) as a line 4 in. from one end. After development of the chromatogram in butanoldioxan-aq. NH3 soln., the distribution ofradioiodine compounds was determined by means of a scanning instrument employing a mica end-window Geiger tube (EW3H, 20th Century Electronics Ltd.) which gave 60 000 counts/min./,c of 131I with a background of 20 counts/min. The mica window was shielded by a brass plate with a 2 mm. slit through which the chromatogram was viewed. The chromatogram was drawn through mechanically at the rate of 1 in./hr., the counts being recorded automatically at the same time. The separated components were eluted into ethanol-aq. 2N-NH3 soln.
(1:1, v/v) and subjected to further chromatography in butanol-acetic acid. Small amounts of carrier compounds were applied to the chromatogram and the labelled iodine compounds were located by means of a radioautograph.
It was found that in 1-5 hr. (defined as fraction A in the preceding paper) was at first thought to consist only of 3:5-di-iodotyrosine and 3:5-di-iodo-4-hydroxyphenyl-lactic acid, which were identified by Fletcher (1957b) . However, monoiodotyrosine was identified among the iodine compounds isolated from one urine (Table 2) , and in another experiment a compound was detected, by means of radioautographs, which was .c400
.E almost immobile in butanol-dioxan-aq. NH3 soln., with a RF lower than that of any of the iodine compounds used as standards ( labelled compounds were extracted into butanol and subjected to paper chromatography in the usual way. The scan of the developed chromatograms (Fig. 2) showed that some hydrolysis had occurred.
A sample of the unhydrolysed compound was therefore purified by paper chromatography. A portion of fraction A was applied to a sheet of chromatography paper (6 in. x 18 in.). The chromatogram was developed in butanol-dioxan-aq.
NH, soln. and cut into strips 1-5 in. wide, which were scanned with a mica end-window Geiger tube. The region of the chromatogram corresponding to the peak near the origin was cut out, and the 1311-labelled compound was eluted into ethanol-aq. v/v) . After concentration of the eluate, the hydrolysis experiment described above was repeated with one-half of the material for a control. The butanol extracts were applied to chromatography paper as spots, followed by solutions of iodine compounds of known structure (approx. 50 ,ug. of each). Some chromatograms were developed in butanol-dioxan-aq. NH3 soln. and some in butanol-acetic acid. Radioautographs were made and staining was done in the usual way. The new component produced by hydrolysis was found to coincide with 3:5-di-iodo-4-hydroxyphenyl.-lactic acid in both solvent systems.
Daily analy8i8 of urinary 131I-labelled compounds Fractionation of the urinary M3I-labelled compounds by a simplified procedure was undertaken to obtain quantitative information about the distribution of 131L. After a patient had received 80 mc of 131I to destroy normal thyroid tissue, 24-hr. urine collections were made as described in the preceding paper. The volume of the total collection was measured, and a sample was taken to determine the 131I content in a liquid-counting apparatus. A sample (10 ml.) of each 24 hr. collection was mixed with 10 ml. of ethanol and adjusted to pH 8-9 with 8 % NaOH. After filtration, the solution was passed through a column of AgCl (1 cm. x 7 cm.), which removed [131I]iodide (Fletcher, 1957a) . The amount of 1311 in the effluent was measured in the liquid-counting apparatus before neutralization with 9 % (w/v) HC1 and concentration to about 5 ml. under reduced pressure at 35-45°. The concentrated solution was taken to pH 1-2 with 9 % (w/v) HCl and extracted I960 336 (Querido, Kassenaar, Meijer & Stanbury, 1956) . A possible metabolic source of monoiodotyrosine is the albumin-like iodoprotein detected in the plasma of patients with thyroid carcinoma after 1"1I therapy (Robbins et al. 1955 ).
[131I]Monoiodotyrosine is the major '31I-labelled compound produced by enzymic hydrolysis of this protein (Robbins et al. 1955; Tata, Rall & Rawson, 1956 ). Labelled 3:5:3'-tri-iodothyronine and thyroxine appear in the urine of thyrotoxic patients (Table 2) 1-2 days after administration of 131I. This early appearance is presumably associated with the rapid turnover of iodine which is characteristic of the disease. Benua & Dobyns (1955) , neither was detected in the urine of patients who had received therapeutic doses for the destruction either of normal tissue or of thyroid-carcinoma tissue.
Labelled 3:3'-di-iodothyronine was detected in rat thyroid (Roche, Michel, Nunez & Wolf, 1955) and in rat plasma after administration of tracer amounts of L311, but in man it is metabolized very rapidly, with a halflife of only 6 hr. (Stanbury & Morris, 1957) . The appearance of 3:3'-di-iodothyronine in the urine of one patient ( 3:3'-di-iodothyronine in relatively high concentration, or some iodine compound (perhaps thyroglobulin) from which it could arise, was present in the circulation at the same time. The structure of the compound which is the main component of fraction B cannot be deduced from the results of hydrolysis experiments. The compound may be formed by the conjugation of 3:5:3'-tri-iodothyronine, which was detected in one experiment, with more than one other substance. Such a conjugate might therefore be hydrolysed at different bonds by f-glucuronidase and by 2N-sodium hydroxide.
The results presented in Table 3 suggest that the labelling of the iodine compounds from which fractions A, B and C are derived occurs by different metabolic processes. A and B, which appear soon after administration of 131I, may be metabolites of labelled iodine compounds released into the circulation by functioning thyroid tissue before its breakdown begins. As the tissue begins to disintegrate as the result of radiation from 131I, labelled thyroglobulin is released into the circulation (Robbins & Rall, 1952; Tata et al. 1956 ). In patients whose normal thyroid tissue is being destroyed by 131I therapy, the concentration of labelled thyroglobulin in the circulation is found to reach a maximum 4-7 days after administration of the dose. Fraction C appears in the urine at this time (Table 3 ) and may therefore arise from the metabolism of thyroglobulin. 3:5-Di-iodotyrosine and 3:5-di-iodo-4-hydroxyphenyl-lactic acid, which form part of fraction A, were shown to be major components of the organic radioiodine on the sixth to seventh day after administration of 131I by Fletcher (1957b) , who suggested that they were metabolites of circulating thyroglobulin. Fraction A, however, appears in the urine (Table 3) [131I]3:3-Di-iodothyronine was detected in the urine of a patient who had received 131I to destroy normal thyroid tissue. 4. A labelled compound isolated from the urine of patients who had received "3"I to destroy either normal thyroid tissue or functioning thyroidcarcinoma tissue was treated with 2N-sodium hydroxide and with ,B-glucuronidase. The product of 2N-sodium hydroxide treatment, other than iodide, was not identified. 3:5:3'-Tri-iodothyronine was detected in one experiment after hydrolysis with ,-glucuronidase.
5.
[131I]Thyroxine and [131I]3:5:3'-tri-iodothyronine were detected in the urine of patients who had received ""1I therapy for thyrotoxicosis.
